Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar vs Metformin and Placebo in Type 2 Diabetes
NCT00263965Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Whole-body insulin sensitivity by assessing the M value during high insulin level euglycemic hyperinsulinemic clamp. Started Aug 2005; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00263965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263965.